Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ARV-471 (Vepdegestrant) is a orally active Cereblon -based estrogen receptor (ER) PROTAC degrader. ARV-471 is developed for the research of breast cancer.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 265.00 | |
5 mg | In stock | $ 657.00 | |
10 mg | In stock | $ 935.00 | |
25 mg | In stock | $ 1,390.00 | |
50 mg | In stock | $ 1,890.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 896.00 |
Description | ARV-471 (Vepdegestrant) is a orally active Cereblon -based estrogen receptor (ER) PROTAC degrader. ARV-471 is developed for the research of breast cancer. |
In vitro | ARV-471 robustly degrades ER with a DC50 of 2 nM in ER-positive breast cancer cell lines[1]. |
In vivo | ARV-471 degrades rat uterine ER and demonstrates no agonist activity in an immature rat uterotrophic model. ARV-471 (3, 10, and 30 mpk; oral) leads to significant tumor volume regressions of estradiol-dependent MCF7 xenografts and concomitant tumor ER protein reductions of >90% at study termination[1]. |
Synonyms | Vepdegestrant |
Molecular Weight | 723.9 |
Formula | C45H49N5O4 |
CAS No. | 2229711-68-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (138.14 mM), sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
ARV-471 2229711-68-4 Endocrinology/Hormones Estrogen Receptor/ERR oral Inhibitor breast cancer PROTAC E3 ligase inhibit hetero-bifunctional ARV 471 ubiquitylation PROTACs Vepdegestrant ARV471 estrogen receptor proteasome inhibitor